Zhaoke Ophthalmology (FRA:9FX) Beta: N/A (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9FX Zhaoke Ophthalmology Ltd FRA:9FX
47 GF Score
Price €0.26
GF Value €0.27
! 5 Warning Signs
View Full Analysis

What is Zhaoke Ophthalmology Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-05), Zhaoke Ophthalmology's Beta is Not available.

Zhaoke Ophthalmology  (FRA:9FX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Zhaoke Ophthalmology Beta Related Terms

Zhaoke Ophthalmology Beta Historical Data

* Premium members only.

The historical data trend for Zhaoke Ophthalmology's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhaoke Ophthalmology Beta Chart

Zhaoke Ophthalmology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Zhaoke Ophthalmology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:9FX
47GF Score
Zhaoke Ophthalmology Ltd FRA:9FX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhaoke Ophthalmology Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Zhaoke Ophthalmology (FRA:9FX) Overvalued in 2026?

Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued. The current stock price of €0.26 is trading 4.4% below its estimated GF Value™ of €0.27.

Key valuation signals for FRA:9FX:

  • Beta: N/A
  • GF Value™: €0.27 vs. price of €0.26 (4.4% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:9FX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhaoke Ophthalmology Business Description

Other Exchanges 06622:Hong Kong
Address No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score

Get the complete analysis for FRA:9FX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.26
Price
€0.27
GF Value